Equity Overview
Price & Market Data
Price: $0.129
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $4,121,269
Daily Volume: 0
Performance Metrics
1 Week: -48.24%
1 Month: -84.73%
3 Months: -84.62%
6 Months: -84.52%
1 Year: -94.40%
YTD: -84.69%
Company Details
Employees: 573
Sector: Health technology
Industry: Biotechnology
Country:
Details
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.